Limited-Stage Hodgkin Lymphoma Minimizing Toxicity

被引:2
|
作者
Straus, David J. [1 ,2 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Div Hematol Oncol, Lymphoma Serv, 1275 York Ave,Box 330, New York, NY 10065 USA
[2] Weill Cornell Med, New York, NY USA
关键词
chemotherapy; combined modality; early-stage classic Hodgkin lymphoma; long-term toxicity; radiation; RADIATION-THERAPY; HEART-DISEASE; HD15; TRIAL; OPEN-LABEL; CHEMOTHERAPY; RADIOTHERAPY; RISK; ABVD; DACARBAZINE; TOMOGRAPHY;
D O I
10.1097/PPO.0000000000000329
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Early-stage classic Hodgkin lymphoma has been highly curable using extended-field radiation therapy (RT) alone, combined-modality therapy consisting of chemotherapy and RT, and more recently chemotherapy alone. Radiation therapy either to an extended field (extended-field RT) or to various iterations of an involved field (involved-field RT) is potentially associated with late morbidity and mortality, particularly second primary cancers and cardiovascular complications. Treatment with chemotherapy alone, when possible, can achieve a high cure rate while avoiding these risks. This review describes the evolution of treatment for early-stage classic Hodgkin lymphoma.
引用
收藏
页码:223 / 229
页数:7
相关论文
共 50 条
  • [1] Limited-Stage Hodgkin Lymphoma: Clarifying Uncertainty
    Meyer, Ralph M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (16) : 1760 - +
  • [2] Management of limited-stage Hodgkin lymphoma
    Al-Juhaishi, Taha
    Ahmed, Sairah
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2023, (01) : 500 - 509
  • [3] Limited-Stage Hodgkin Lymphoma: Managing Uncertainty
    Meyer, Ralph M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (12) : 1180 - 1182
  • [4] The Case for Chemotherapy Alone for Limited-Stage Hodgkin's Lymphoma
    Connors, Joseph M.
    ONCOLOGIST, 2012, 17 (08) : 1011 - 1013
  • [5] Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma
    Abramson, Jeremy S.
    Amason, Jon E.
    LaCasce, Ann S.
    Redd, Robert
    Barnes, Jeffrey A.
    Sokol, Lubomir
    Joyce, Robin
    Avigan, David
    Neuberg, Donna
    Takvorian, Ronald W.
    Hochberg, Ephraim P.
    Bello, Celeste M.
    BLOOD, 2019, 134 (07) : 606 - 613
  • [6] Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma
    Abramson, Jeremy S.
    Bengston, Elizabeth
    Redd, Robert
    Barnes, Jeffrey A.
    Takvorian, Tak
    Sokol, Lubomir
    Lansigan, Frederick
    Armand, Philippe
    Shah, Bijal
    Jacobsen, Eric
    Martignetti, Rosalba
    Turba, Elyce
    Metzler, Sara
    Patterson, Victoria
    LaCasce, Ann S.
    Bello, Celeste M.
    BLOOD ADVANCES, 2023, 7 (07) : 1130 - 1136
  • [7] Limited-stage mantle-cell lymphoma
    Leitch, HA
    Gascoyne, RD
    Chhanabhai, M
    Voss, NJ
    Klasa, R
    Connors, JM
    ANNALS OF ONCOLOGY, 2003, 14 (10) : 1555 - 1561
  • [8] End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma
    Barnes, J. A.
    LaCasce, A. S.
    Zukotynski, K.
    Israel, D.
    Feng, Y.
    Neuberg, D.
    Toomey, C. E.
    Hochberg, E. P.
    Canellos, G. P.
    Abramson, J. S.
    ANNALS OF ONCOLOGY, 2011, 22 (04) : 910 - 915
  • [9] ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma
    Park, Steven, I
    Shea, Thomas C.
    Olajide, Oludamilola
    Reddy, Nishitha M.
    Budde, Lihua E.
    Ghosh, Nilanjan
    Deal, Allison M.
    Noe, Jeanne F.
    Ansell, Stephen M.
    BLOOD ADVANCES, 2020, 4 (11) : 2548 - 2555
  • [10] Treatment of Favorable, Limited-Stage Hodgkin's Lymphoma With Chemotherapy Without Consolidation by Radiation Therapy
    Canellos, George P.
    Abramson, Jeremy S.
    Fisher, David C.
    LaCasce, Ann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (09) : 1611 - 1615